Gainers:
Navistar International Corp. (NAV) is up over 3 percent to $37.89. The company's fourth quarter profit surged from the year-ago quarter. Net sales and revenues also jumped from previous year, but were below consensus.
Jefferies Group, Inc. (JEF) is up 6 percent to $12.50. The company's fourth quarter earnings declined from prior year, yet were above Wall Street view. The company also declared a quarterly dividend of $0.075 per share of common stock.
CVS Caremark Corp. (CVS) is up nearly 3 percent to $37.60. The company confirmed its 2011 outlook and provided 2012 guidance. The company expressed confidence in its short and long-term growth targets. The company also announced quarterly dividend increase of 30 percent.
Salix Pharmaceuticals Ltd. (SLXP) is gaining 10 percent to $47.50. Progenics Pharmaceuticals, Inc. (PGNX) is up 15 percent to $7.50. The companies announced the outcome of Phase 3 trial to evaluate efficacy and safety of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. This trial showed highly statistically significant results for the primary endpoint in two of the three treatment arms when compared to the placebo treatment arm.
Canadian Solar Inc. (CSIQ) is up 33 percent to $2.93. The company's wholly owned subsidiary, Canadian Solar Solutions Inc. has entered into a sales agreement with TransCanada Corp. (TRP) for the sale of a 86 megawatts AC solar project portfolio for approximately C$470 million.
Decliners:
AT&T, Inc. (T) is falling nearly 1 percent to $28.48. The company agreed with Deutsche Telekom AG (DTEGY.PK) to terminate its bid to acquire T-Mobile USA Inc. after a review of all options amid stiff opposition from regulators. Due to the termination, AT&T will take a pretax charge of $4 billion in the fourth quarter 2011.
General Mills, Inc. (GIS) is falling nearly 4 percent to $38.13. The company's second quarter profit declined from the year-ago quarter, although it backed its fiscal 2012 earnings guidance.
AstraZeneca plc (AZN) is down over 1 percent to $44.90. The company announced that its core earnings per share for 2011 are likely to be at the low end of its previously issued guidance range due to impairment charges stemming from two studies. The company expects to record pre-tax impairment charges of $381.5 million in the fourth quarter, with the charge expected to have an impact of about $0.21 on core earnings per share.
Targacept, Inc. (TRGT) is down 23 percent to $6.00 based on the news that RENAISSANCE 2 study did not meet its primary endpoint of change in the Montgomery-Asberg Depression Rating Scale total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo.
For comments and feedback: editorial@rttnews.com